RICHMOND, British Columbia, July 20, 2011 (GLOBE NEWSWIRE) -- BioCurex, Inc. (OTCBB:BOCX) announced today that Paul D. Slowey, Ph.D. has joined the company as President with responsibilities in marketing and management of OncoPet Diagnostics and supporting the broader licensing efforts of the company in general. Dr. Slowey has extensive experience in diagnostic products and with the company's technology and served as BioCurex CEO in 2001-2002. He has been a consultant to BioCurex for the past three years.
"I could not be more pleased to have been asked to take on the responsibilities as President of BioCurex", stated Dr. Slowey. "I believe that I can have a significant impact in helping the management team reach its goals of short term revenue generation and financial independence down the road."
BioCurex has also appointed two new directors to its Board of Directors; Paul D. Slowey, Ph.D., its new President, and Trent Davis, President and CEO of Paulson Investment Company. Trent Davis has held various positions at Paulson Investment Company and brings extensive experience in capital markets and investor relations to the board.
"As CEO of Paulson and head of the Syndicate Department for Paulson financings, I was intimately involved in the financing of BioCurex in January of 2010," commented Mr. Davis. "I am pleased to bring my financial experience and commitment to the BioCurex Board."
Dr. Ricardo Moro, BioCurex CEO stated, "These additions to our management team bring experienced new blood into the company. I have known Dr. Slowey for over a decade now and we have experience working very well as a team. This is a welcome addition that strengthens the marketing and business development focus of the Company." Commenting of the board additions, Dr. Moro stated, "Adding this depth of experience both on the financial and business sides will expedite the process for reaching our goals."
About Paul D. Slowey, Ph.D.
Dr. Paul Slowey has been President and CEO of Oasis Diagnostics Corporation since 2007 and Managing Member of Bamburgh Marrsh LLC since 2002. Previously he held various diagnostic positions including; Director of International Sales for OraSure (formerly Epitope), Chief Operating Officer for Saliva Diagnostics, Director of International Sales for Incstar Corp. [now DiaSorin]. He holds a B.S. (Honors) from Sheffield Polytechnic (England), a Ph.D. in Organic Chemistry from the University of Newcastle-Upon-Tyne (England) and Post-Doctoral Fellowships from University of Victoria and Memorial University of Newfoundland (Canada).
About Trent Davis
Trent Davis has been with Paulson Investment Company, Inc. (Paulson) since 1991, and has served as Paulson Investment's President and CEO since 2005. Prior to being appointed as President and CEO, Mr. Davis served as Senior Vice President of Paulson's Syndicate Department. Mr. Davis is credited with bolstering the firm's Syndicate Department, overseeing the syndication of over 50 public and private offerings and raising approximately $600 million. Mr. Davis served as a board member and Chairman of the National Investment Banking Association. Mr. Davis holds a B.S. in Business and Economics from Linfield College, and has earned a Master's Degree in Business Administration from the University of Portland.
About BioCurex, Inc.
BioCurex, Inc. is a biotechnology company that is developing products based on patented and proprietary technology in the area of cancer diagnostics. The technology identifies a universal cancer marker known as RECAF.
RECAF is a molecule that is present on cancer cells but not detected in significant levels on healthy cells or benign tumor cells. It is the receptor for alpha-fetoprotein and is classified as an oncofetal antigen due to its presence on both fetal and malignant tissues. This characteristic makes RECAF a more accurate indicator of cancer than most current tumor markers.
BioCurex is commercializing its technology through licensing arrangements with companies that develop and market diagnostic tests for the large automated clinical laboratory setting, through development and marketing of non-automated clinical laboratory tests, through development of rapid, point-of-care test formats, and through marketing of its OncoPet RECAF test for cancer in companion animals.
BioCurex has signed licensing agreements for its cancer detection blood tests with Abbott Laboratories (NYSE:ABT) and with Alere (NYSE:ALR), formerly Inverness Medical Innovations (NYSE:IMA).
For further information on these agreements visit: http://sec.gov/Archives/edgar/data/1092562/000100487808000117/sb2amnd4s1april08.txt.
For more information about the Company, please visit www.BioCurex.com/" target="_top" rel="nofollow">www.BioCurex.com.
For more information about OncoPet Diagnostics Inc., please visit: www.OncoPetDiagnostics.com/" target="_top" rel="nofollow">www.OncoPetDiagnostics.com.
Forward-Looking Statements
The Company has not authorized the release of this information in any form that contravenes the Communication Act and will not be responsible for unsolicited massive distribution of this material by e-mail or facsimile by unauthorized parties. Statements in this press release, which are not historical facts, are "forward-looking statements'' within the meaning given to that term in the Private Securities Litigation Reform Act of 1995. The Company intends that such forward-looking statements be subject to the safe harbors created thereby. Since these statements involve risks and uncertainties and are subject to change at any time, the Company's actual results could differ materially from expected results.